|  |  |  |
| --- | --- | --- |
| **Parameter** | **AGO-OVAR 11** | **Data on original studies included to the meta analyses by Riester et al., Liu et al. and Tucker et al.**  |
| % of patients w vs w/o complete resection | N=104 RD0 and N=162 RD>0 | 1. N=257 RD≤1 vs N=264 RD>12. N=13 RD0 and N=41 RD>03. N= 22 RD0 vs N=21 RD<2 cm vs N=109 RD>2 cm4. N=57 RD ≤1 and N=53 RD>15. N=95 RD ≤1 and N=22 RD>16. N=71 RD ≤1 and N=29 RD>17. N=92 RD ≤1 and N=93 RD>18. N=64 RD ≤1 and N=16 RD>19. N=103 RD ≤1 and N=157 RD>110. N=68 RD0 and N=164 RD>011. N=63 RD ≤1 and N=56 RD>112. N=223 RD0 vs N=342 RD>0 |
| Location of tumor sample collection | not reported | 1.-12. not reported |
| Frozen/ FFPE | FFPE | 1. FFPE2. fresh frozen3. fresh frozen4. fresh frozen5. fresh frozen and FFPE6. fresh frozen7. fresh frozen8. not reported9. fresh frozen10. fresh frozen11. fresh frozen12. fresh frozen |
| Quality features tumor vs. stroma | >70% tumor | 1. selected areas for sampling were based on having low levels of infiltrating, necrotic, or other contaminating non-tumor tissue.2. ≥50% tumor3. median percentage tumor cells: 70%, interquartile range: 50%–80%4. > 80% of tumor cells5. microdissection of from 5,000 dissected tumor cells6. not reported7. ≥80% tumor8. ≥75% cancer cells9. > 70% tumor cells10. 92.5% ≥50% tumor; 7.5% tumor 30%-49%11. > 70% tumor cells12. 70% tumor cell nuclei with less than 20% necrosis |
| Determination of residual disease | surgeon at the end of surgery | 1.-11. not reported12. surgeon at the end of surgery |
| Gene expression analyses platform | Whole-Genome DASL HT assay with the HumanRef-8 Bead Chip | 1. Illumina HumanRef-8 v22. Custom made3. Operon Human v3 4. Agilent G4112a5. Affymetrix U133 Plus 2.06. Affymetrix U95 v7. Affymetrix U133A8. TaqManqRT-PCR9. Agilent G4112a10. Affymetrix U133 Plus 11. Affymetrix U133a12. Affymetrix HT U133a |

Supplement Table 1: Description of the resource data of the meta analyses conducted by Riester et al., Liu et.al. and Tucker et al. in comparison to the AGO-OVAR 11/ ICON 7 samples; 1. Bentink et al. [[34](#_ENREF_34)]; 2. Partheen et al.[[35](#_ENREF_35)]; 3. Crijns et al. [[36](#_ENREF_36)]; 4. Yoshihara et al. [[37](#_ENREF_37)]; 5. Mok et al. [[38](#_ENREF_38)]; 6. Konstantinopoulos et al. [[39](#_ENREF_39)]; 7. Bonome et al. [[40](#_ENREF_40)]; 8. Gillet et al. [[41](#_ENREF_41)]; 9. Yoshihara et al. [[42](#_ENREF_42)]; 10. Tothill et al. [[43](#_ENREF_43)]; 11. Dressman et al. [[44](#_ENREF_44)]; 12. TCGA [[18](#_ENREF_18)]; Liu et al. undertook a meta analyses including 7., 10. and 12; Tucker et al. undertook a meta analyses of 10. and 12. TCGA.